+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Orphan Drugs Market Analysis 2019

  • ID: 4857807
  • Report
  • October 2019
  • Region: Global
  • 162 pages
  • Syngene Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Celgene Corporation
  • GlaxoSmithKline Plc.
  • Hoffmann-La Roche Ltd.
  • MORE
The Global Orphan Drugs market is expected to reach $398.93 billion by 2026 growing at a CAGR of 13.0% during the forecast period. Drugs that are used to treat rare diseases are referred to as orphan drugs. Orphan disease, by definition, is subjected as any disease that affects a small percentage of the population that are often life-threatening, chronic, progressive, degenerative, and disabling, and while most of them are allied to a genetic disorder and remain undiagnosed.

The demand for orphan drugs has increased significantly owing to the surge in prevalence of rare diseases. However, the limited patient pool for clinical trials and product marketing is hampering the market. Moreover, growth in novel indications for known orphan drugs and untapped emerging economies are expected to provide new market opportunities to orphan drug manufacturers in the near future.

Based on the Therapy Class, the Oncology segment is estimated to have a lucrative growth due to the rise in the number of patients suffering from different types of cancers. This also increases the demand for novel therapeutics, which as per the report will bode well for the global orphan drugs market.

The key vendors mentioned are Alexion Pharmaceuticals Inc, Amgen Inc, AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company Limited, GlaxoSmithKline Plc, Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd.

Drug Types Covered:
  • Biologics
  • Non-Biologics
Therapy Classes Covered:
  • Blood
  • Central Nervous Systems
  • Endocrine
  • Respiratory
  • Dermatology
  • Systemic Anti-Infective
  • Musculoskeletal
Drugs Covered:
  • Adcetris
  • Darzalex
  • Imbruvica
  • Jakaf
  • Keytruda
  • Opdivo
  • Pomalyst
  • Revlimid
  • Rituxan
  • Soliris
  • Spinraza
  • Copaxone
  • Avonex
  • Sensipar
  • Hemlibra
  • Venclexta
  • Epidiolex
Disease Types Covered:
  • Cardiovascular Diseases
  • Hematologic and Immunologic Diseases
  • Infectious Diseases
  • Metabolic Diseases
  • Neurologic Diseases
  • Oncological Diseases
  • Gastrointestinal
  • Pulmonary
Indications Covered:
  • Acute Myeloid Lukemia
  • Cystic Fibrosis
  • Duchenne Muscular Dystrophy
  • Glioma
  • Graft vs Host Disease
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • Ovarian Cancer
  • Pancreatic Cancer
  • Renal Cell Carcinoma
  • Other Indications
Phases Covered:
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
Distribution Channels Covered:
  • Hospital Pharmacy
  • Online Sales
  • Retail Pharmacy
  • Speciality Pharmacies
  • Other Distribution Channels
Regions Covered:
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa
Key Questions Answered in this Report:
  • How this market evolved since the year 2016
  • Market size estimations, forecasts and CAGR for all the segments presented in the scope
  • Key Market Developments and financials of the key players
  • Opportunity Analysis for the new entrants
  • SWOT Analysis of the key players
  • Fastest growing markets analyzed during the forecast period

*Please Note: This report will be delivered within 48 hours of ordering.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Celgene Corporation
  • GlaxoSmithKline Plc.
  • Hoffmann-La Roche Ltd.
  • MORE
1 Market Synopsis

2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources

3 Market Dynamics
3.1 Drivers
3.2 Restraints

4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Orphan Drugs Market, By Drug Type
5.1 Introduction
5.2 Biologics
5.3 Non-Biologics

6 Global Orphan Drugs Market, By Therapy Class
6.1 Introduction
6.2 Blood
6.3 Central Nervous Systems
6.4 Endocrine
6.5 Respiratory
6.6 Dermatology
6.7 Systemic Anti-Infectives
6.8 Musculoskeletal

7 Global Orphan Drugs Market, By Drug
7.1 Introduction
7.2 Adcetris
7.3 Darzalex
7.4 Imbruvica
7.5 Jakaf
7.6 Keytruda
7.7 Opdivo
7.8 Pomalyst
7.9 Revlimid
7.10 Rituxan
7.11 Soliris
7.12 Spinraza
7.13 Copaxone
7.14 Avonex
7.15 Sensipar
7.16 Hemlibra
7.17 Venclexta
7.18 Epidiolex

8 Global Orphan Drugs Market, By Disease Type
8.1 Introduction
8.2 Cardiovascular Diseases
8.3 Hematologic and Immunologic Diseases
8.4 Infectious Diseases
8.5 Metabolic Diseases
8.6 Neurologic Diseases
8.7 Oncological Diseases
8.8 Gastrointestinal
8.9 Pulmonary

9 Global Orphan Drugs Market, By Indication
9.1 Introduction
9.2 Acute Myeloid Lukemia
9.3 Cystic Fibrosis
9.4 Duchenne Muscular Dystrophy
9.5 Glioma
9.6 Graft vs Host Disease
9.7 Multiple Myeloma
9.8 Non-Hodgkin's Lymphoma
9.9 Ovarian Cancer
9.10 Pancreatic Cancer
9.11 Renal Cell Carcinoma
9.12 Other Indications

10 Global Orphan Drugs Market, By Phase
10.1 Introduction
10.2 Phase I
10.3 Phase II
10.4 Phase III
10.5 Phase IV

11 Global Orphan Drugs Market, By Distribution Channel
11.1 Introduction
11.2 Hospital Pharmacy
11.3 Online Sales
11.4 Retail Pharmacy
11.5 Specialty Pharmacies
11.6 Other Distribution Channels

12 Global Orphan Drugs Market, By Geography
12.1 North America
12.2 Europe
12.3 Asia Pacific
12.4 South America
12.5 Middle East & Africa

13 Strategic Benchmarking

14 Vendors Landscape
14.1 Alexion Pharmaceuticals Inc.
14.2 Amgen Inc.
14.3 AstraZeneca Plc.
14.4 Bayer AG
14.5 Bristol-Myers Squibb Company
14.6 Celgene Corporation
14.7 Daiichi Sankyo Company Limited
14.8 GlaxoSmithKline Plc.
14.9 Hoffmann-La Roche Ltd.
14.10 Merck & Co. Inc.
14.11 Novartis AG
14.12 Novo Nordisk A/S
14.13 Teva Pharmaceutical Industries Ltd

List of Data Tables
Table 1 Global Orphan Drugs Market Outlook, By Region (2016-2026) ($MN)
Table 2 Global Orphan Drugs Market Outlook, By Drug Type (2016-2026) ($MN)
Table 3 Global Orphan Drugs Market Outlook, By Biologics (2016-2026) ($MN)
Table 4 Global Orphan Drugs Market Outlook, By Non-Biologics (2016-2026) ($MN)
Table 5 Global Orphan Drugs Market Outlook, By Therapy Class (2016-2026) ($MN)
Table 6 Global Orphan Drugs Market Outlook, By Blood (2016-2026) ($MN)
Table 7 Global Orphan Drugs Market Outlook, By Central Nervous Systems (2016-2026) ($MN)
Table 8 Global Orphan Drugs Market Outlook, By Endocrine (2016-2026) ($MN)
Table 9 Global Orphan Drugs Market Outlook, By Respiratory (2016-2026) ($MN)
Table 10 Global Orphan Drugs Market Outlook, By Dermatology (2016-2026) ($MN)
Table 11 Global Orphan Drugs Market Outlook, By Systemic Anti-Infectives (2016-2026) ($MN)
Table 12 Global Orphan Drugs Market Outlook, By Musculoskeletal (2016-2026) ($MN)
Table 13 Global Orphan Drugs Market Outlook, By Drug (2016-2026) ($MN)
Table 14 Global Orphan Drugs Market Outlook, By Adcetris (2016-2026) ($MN)
Table 15 Global Orphan Drugs Market Outlook, By Darzalex (2016-2026) ($MN)
Table 16 Global Orphan Drugs Market Outlook, By Imbruvica (2016-2026) ($MN)
Table 17 Global Orphan Drugs Market Outlook, By Jakaf (2016-2026) ($MN)
Table 18 Global Orphan Drugs Market Outlook, By Keytruda (2016-2026) ($MN)
Table 19 Global Orphan Drugs Market Outlook, By Opdivo (2016-2026) ($MN)
Table 20 Global Orphan Drugs Market Outlook, By Pomalyst (2016-2026) ($MN)
Table 21 Global Orphan Drugs Market Outlook, By Revlimid (2016-2026) ($MN)
Table 22 Global Orphan Drugs Market Outlook, By Rituxan (2016-2026) ($MN)
Table 23 Global Orphan Drugs Market Outlook, By Soliris (2016-2026) ($MN)
Table 24 Global Orphan Drugs Market Outlook, By Spinraza (2016-2026) ($MN)
Table 25 Global Orphan Drugs Market Outlook, By Copaxone (2016-2026) ($MN)
Table 26 Global Orphan Drugs Market Outlook, By Avonex (2016-2026) ($MN)
Table 27 Global Orphan Drugs Market Outlook, By Sensipar (2016-2026) ($MN)
Table 28 Global Orphan Drugs Market Outlook, By Hemlibra (2016-2026) ($MN)
Table 29 Global Orphan Drugs Market Outlook, By Venclexta (2016-2026) ($MN)
Table 30 Global Orphan Drugs Market Outlook, By Epidiolex (2016-2026) ($MN)
Table 31 Global Orphan Drugs Market Outlook, By Disease Type (2016-2026) ($MN)
Table 32 Global Orphan Drugs Market Outlook, By Cardiovascular Diseases (2016-2026) ($MN)
Table 33 Global Orphan Drugs Market Outlook, By Hematologic and Immunologic Diseases (2016-2026) ($MN)
Table 34 Global Orphan Drugs Market Outlook, By Infectious Diseases (2016-2026) ($MN)
Table 35 Global Orphan Drugs Market Outlook, By Metabolic Diseases (2016-2026) ($MN)
Table 36 Global Orphan Drugs Market Outlook, By Neurologic Diseases (2016-2026) ($MN)
Table 37 Global Orphan Drugs Market Outlook, By Oncological Diseases (2016-2026) ($MN)
Table 38 Global Orphan Drugs Market Outlook, By Gastrointestinal (2016-2026) ($MN)
Table 39 Global Orphan Drugs Market Outlook, By Pulmonary (2016-2026) ($MN)
Table 40 Global Orphan Drugs Market Outlook, By Indication (2016-2026) ($MN)
Table 41 Global Orphan Drugs Market Outlook, By Acute Myeloid Lukemia (2016-2026) ($MN)
Table 42 Global Orphan Drugs Market Outlook, By Cystic Fibrosis (2016-2026) ($MN)
Table 43 Global Orphan Drugs Market Outlook, By Duchenne Muscular Dystrophy (2016-2026) ($MN)
Table 44 Global Orphan Drugs Market Outlook, By Glioma (2016-2026) ($MN)
Table 45 Global Orphan Drugs Market Outlook, By Graft vs Host Disease (2016-2026) ($MN)
Table 46 Global Orphan Drugs Market Outlook, By Multiple Myeloma (2016-2026) ($MN)
Table 47 Global Orphan Drugs Market Outlook, By Non-Hodgkin's Lymphoma (2016-2026) ($MN)
Table 48 Global Orphan Drugs Market Outlook, By Ovarian Cancer (2016-2026) ($MN)
Table 49 Global Orphan Drugs Market Outlook, By Pancreatic Cancer (2016-2026) ($MN)
Table 50 Global Orphan Drugs Market Outlook, By Renal Cell Carcinoma (2016-2026) ($MN)
Table 51 Global Orphan Drugs Market Outlook, By Other Indications (2016-2026) ($MN)
Table 52 Global Orphan Drugs Market Outlook, By Phase (2016-2026) ($MN)
Table 53 Global Orphan Drugs Market Outlook, By Phase I (2016-2026) ($MN)
Table 54 Global Orphan Drugs Market Outlook, By Phase II (2016-2026) ($MN)
Table 55 Global Orphan Drugs Market Outlook, By Phase III (2016-2026) ($MN)
Table 56 Global Orphan Drugs Market Outlook, By Phase IV (2016-2026) ($MN)
Table 57 Global Orphan Drugs Market Outlook, By Distribution Channel (2016-2026) ($MN)
Table 58 Global Orphan Drugs Market Outlook, By Hospital Pharmacy (2016-2026) ($MN)
Table 59 Global Orphan Drugs Market Outlook, By Online Sales (2016-2026) ($MN)
Table 60 Global Orphan Drugs Market Outlook, By Retail Pharmacy (2016-2026) ($MN)
Table 61 Global Orphan Drugs Market Outlook, By Specialty Pharmacies (2016-2026) ($MN)
Table 62 Global Orphan Drugs Market Outlook, By Other Distribution Channels (2016-2026) ($MN)
Table 63 North America Orphan Drugs Market Outlook, By Drug Type (2016-2026) ($MN)
Table 64 North America Orphan Drugs Market Outlook, By Therapy Class (2016-2026) ($MN)
Table 65 North America Orphan Drugs Market Outlook, By Drug (2016-2026) ($MN)
Table 66 North America Orphan Drugs Market Outlook, By Disease Type (2016-2026) ($MN)
Table 67 North America Orphan Drugs Market Outlook, By Indication (2016-2026) ($MN)
Table 68 North America Orphan Drugs Market Outlook, By Phase (2016-2026) ($MN)
Table 69 North America Orphan Drugs Market Outlook, By Distribution Channel (2016-2026) ($MN)
Table 70 Europe Orphan Drugs Market Outlook, By Drug Type (2016-2026) ($MN)
Table 71 Europe Orphan Drugs Market Outlook, By Therapy Class (2016-2026) ($MN)
Table 72 Europe Orphan Drugs Market Outlook, By Drug (2016-2026) ($MN)
Table 73 Europe Orphan Drugs Market Outlook, By Disease Type (2016-2026) ($MN)
Table 74 Europe Orphan Drugs Market Outlook, By Indication (2016-2026) ($MN)
Table 75 Europe Orphan Drugs Market Outlook, By Phase (2016-2026) ($MN)
Table 76 Europe Orphan Drugs Market Outlook, By Distribution Channel (2016-2026) ($MN)
Table 77 Asia Pacific Orphan Drugs Market Outlook, By Drug Type (2016-2026) ($MN)
Table 78 Asia Pacific Orphan Drugs Market Outlook, By Therapy Class (2016-2026) ($MN)
Table 79 Asia Pacific Orphan Drugs Market Outlook, By Drug (2016-2026) ($MN)
Table 80 Asia Pacific Orphan Drugs Market Outlook, By Disease Type (2016-2026) ($MN)
Table 81 Asia Pacific Orphan Drugs Market Outlook, By Indication (2016-2026) ($MN)
Table 82 Asia Pacific Orphan Drugs Market Outlook, By Phase (2016-2026) ($MN)
Table 83 Asia Pacific Orphan Drugs Market Outlook, By Distribution Channel (2016-2026) ($MN)
Table 84 South America Orphan Drugs Market Outlook, By Drug Type (2016-2026) ($MN)
Table 85 South America Orphan Drugs Market Outlook, By Therapy Class (2016-2026) ($MN)
Table 86 South America Orphan Drugs Market Outlook, By Drug (2016-2026) ($MN)
Table 87 South America Orphan Drugs Market Outlook, By Disease Type (2016-2026) ($MN)
Table 88 South America Orphan Drugs Market Outlook, By Indication (2016-2026) ($MN)
Table 89 South America Orphan Drugs Market Outlook, By Phase (2016-2026) ($MN)
Table 90 South America Orphan Drugs Market Outlook, By Distribution Channel (2016-2026) ($MN)
Table 91 Middle East & Africa Orphan Drugs Market Outlook, By Drug Type (2016-2026) ($MN)
Table 92 Middle East & Africa Orphan Drugs Market Outlook, By Therapy Class (2016-2026) ($MN)
Table 93 Middle East & Africa Orphan Drugs Market Outlook, By Drug (2016-2026) ($MN)
Table 94 Middle East & Africa Orphan Drugs Market Outlook, By Disease Type (2016-2026) ($MN)
Table 95 Middle East & Africa Orphan Drugs Market Outlook, By Indication (2016-2026) ($MN)
Table 96 Middle East & Africa Orphan Drugs Market Outlook, By Phase (2016-2026) ($MN)
Table 97 Middle East & Africa Orphan Drugs Market Outlook, By Distribution Channel (2016-2026) ($MN)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Alexion Pharmaceuticals Inc.
  • Amgen Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Company Limited
  • GlaxoSmithKline Plc.
  • Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Teva Pharmaceutical Industries Ltd
Note: Product cover images may vary from those shown
Adroll
adroll